HRT, breast and endometrial cancers: Strategies and intervention options

Maturitas

Volumn 32, Issue 3, 1999, Pages 131-139

  Sismondi, Piero ^a   Biglia, Nicoletta ^a   Giai, Maurizia ^a   Ponzone, Riccardo ^a   Roagna, Riccardo ^a   Sgro, Luca ^a   Campagnoli, Carlo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Breast cancer; Gynecological cancer; HRT

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAMMOGRAPHY; MENOPAUSE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032806064     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00108-X     Document Type: Article

References (33)

1. Cline J.M., Soderqwist G., von Schoultz E. et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 174:1996;93-100.
2. Steinberg K.K., Thacker S.B., Smith S.J. et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc. 265:1991;1985-1990.
3. Grady D., Rubin S.M., Petitti D.B. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
4. Sillero-Arenas M., Delgado-Rodriguez M., Rodriguez-Canteras R., Bueno-Cavanillas A., Galvez-Vergas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 79:1992;286-294.
5. Colditz G.A., Egan K.M., Stampfer M.J. et al. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 168:1993;1473-1480.
6. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 10 8411 women without breast cancer. Lancet. 350:1997;1047-1059.
7. Kennedy D.L., Baum C., Forbes M.B. Non-contraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 65:1985;441.
8. Campagnoli C., Biglia N., Peris C., Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol. 9:1995;67-74.
9. Campagnoli C., Biglia N., Altare F. et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol. 7:1993;251-258.
10. Colditz G.A., Hankinson S.E., Hunter D.J. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med. 332:1995;1589-1593.
11. Stanford J., Weiss N., Voigt L. et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc. 274:1995;137-142.
12. Newcomb P.A., Longnecker M.P., Storer B.E. et al. Long term hormone replacement therapy and risk of breast cancer in post menopausal women. Am J Epidemiol. 142:1995;788-795.
13. Bergkvist L., Adami H.O., Persson I. et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. New Engl J Med. 321:1989;293-297.
14. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer. 42:1988;832-838.
15. Persson I., Thurfjell E., Bergström R., Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer. 72:1997;758-761.
16. Campagnoli C., Biglia N., Lanza M. et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women: preliminary report. Maturitas. 19:1994;25-31.
17. Campagnoli C, Biglia N, Giai M, Sismondi P. Progestins and breast cancer risk. Zentralb Gynakol. 119(Suppl 2):1997;38-42.
18. Sismondi P., Biglia N., Giai M., Campagnoli C. Hormone replacement therapy and breast cancer. Eur Menopause J. 3:1996;227-231.
19. Harvey J.A., Pinkerton J.V., Herman C.R. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst. 89:1997;1623-1625.
20. Laya M.B., Larson E.B., Taplin S.H., White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 88:1996;643-649.
21. McNicholas M.M.J., Heneghan J.P., Milner M.H. et al. Pain and increased mammographic density in women receiving hormone replacement therapy. Am J Roentgenol. 163:1994;311-315.
22. Thurfjell E.L., Holmberg L.H., Persson I.R. Screening mammograpy: sensitivity and specificity in relation to hormone replacement therapy. Radiology. 203:1997;339-341.
23. Persson I., Thurfjell E., Holmberg L. Effect of estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol. 15:1997;3201-3207.
24. Laya M.B., Gallagher C., Schreimad J. et al. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology. 196:1995;433-437.
25. Grady D., Gebretsadik T., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 85:1995;304-313.
26. Voigt L., Weiss N., Chu J. et al. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer. Lancet. 338:1991;274-277.
27. Brinton L., Hoover R. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol. 81:1993;265-271.
28. Pike M.C., Peters R.K., Cozen W. et al. Estrogen-progestin replacement therapy and endometrial cancer. J Nat Cancer Inst. 89:1997;1110-1116.
29. Beresford S.A.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet. 349:1997;458-461.
30. Effects of HRT on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc. 275(5):1996;370-375.
31. Woodruuff J.D., Pickar J.H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 170(5):1994;1213-1223.
32. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 67(3):1996;327-332.
33. Cerin A., Heldaas K., Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. New Engl J Med. 334:1996;668-669.